Grants

Filtering by: “Bloom Syndrome”

Bloom Syndrome Grant Program - Full Application (by invitation only)
Oct
15
to Nov 22

Bloom Syndrome Grant Program - Full Application (by invitation only)

 
 

Bloom Syndrome Grant Program


The Bloom Syndrome Association, in collaboration with The Orphan Disease Center (ODC) at the University of Pennsylvania is pleased to announce the Bloom Syndrome Grant Program. Bloom syndrome (BSyn) is an ultra-rare multi system disorder that substantially increases the risk of developing cancer at an early age. While only about ~300 cases have been reported to date, BSyn is part of a group of rare DNA damage response and repair disorders. The gene BLM, located at 15q26.1, encodes for the BLM protein, a RecQ DNA Helicase family protein. A recurrent mutation known as BLMAsh, which is common among Ashkenazi Jews, is responsible for approximately 30% of BSyn cases, while the remaining 70% of cases are caused by multiple other mutations with full or partial loss of function and a range of resulting phenotypes.

BLM pathogenic variants that cause Bloom syndrome result in DNA repair defects which in turn result in chromosome breakages and rearrangements. The abnormal DNA repair is responsible for the increased risk for cancer. Greater knowledge of its mechanisms will be not only beneficial for patients with Bloom syndrome but may also translate into clinical innovations for cancer therapy in general.

We are seeking grant applications to increase the rate of discovery of the mechanisms of BSyn and, importantly, lead to treatments and/or cures for BSyn. While the RFA is intentionally broad in scope, priority will be given to grants that cover the following areas:

  1. Improve knowledge of Bloom syndrome tumor biology, including, but not limited to tumor models, tumor sequencing to determine a tumor signature for BSyn, molecular surveillance for tumors, as well as a centralized registry of validated tissue (coordination of sampling, storing and distribution of samples). One 2-year grant for up to $150,000 (total cost).

  2. Literature review, critical assessment & study proposal, regarding:

      i.        The impact of sunlight and radiation in BSyn.

      ii.        Safety & efficacy of cancer treatments in BSyn including modalities, regimes and dosages.

    iii.        Utility of existing data sets as a natural history study and/or control arm for future clinical trials.

    iv.        Gene therapy for BSyn.

    v.         Why and how BSyn can be a model for cancer development in general.

    These projects will involve a critical review of currently available information and outline proposed studies that could be performed to better understand the topic(s) in question. Up to four one-year grants for up to $50,000 each (total cost).

  3.  Global cancer surveillance & novel cancer research in Bloom Syndrome, including, but not limited to, establishment of BSyn tumor organoids, collection and analyses of patient-derived blood samples, microbiome studies, and hematopoietic stem cell health and dysfunction studies. One 2-year grant for up to $150,000 (total cost).


Eligibility

Non-profits. All individuals holding a faculty-level appointment at an academic institution or a senior position at a non-profit institution or foundation are eligible to respond to this RFA.

Commercial entities. We will consider applications from commercial entities if a principal investigator of appropriate experience is identified.

Intellectual property created as a result of this funding will be assigned to the home institution of the inventors who presumably would be employees of the company. We expect that grants provided to commercial entities be matched dollar for dollar. Note that the budget should cover the entire scope of work and should include the Bloom Syndrome Association award and the company’s match. We will need assurance in the grant contract that the company will diligently develop the project.


Full Applications are due Friday, November 22, 2024 by 8pm ET.

To Apply:

  1. Please review the Bloom Syndrome Grant Program RFA Guidelines.

  2. Download and complete the below forms:

3. Complete the Application Form on Submittable.



For any scientific inquiries regarding this grant please email Debbie Requesens

For any administrative inquiries regarding this grant please email psom-odcadmin@pobox.upenn.edu

View Event →
Bloom Syndrome Grant Program
Sep
2
to Sep 27

Bloom Syndrome Grant Program

 
 

Bloom Syndrome Grant Program

The Bloom Syndrome Association, in collaboration with The Orphan Disease Center (ODC) at the University of Pennsylvania is pleased to announce the Bloom Syndrome Grant Program. Bloom syndrome (BSyn) is an ultra-rare multi system disorder that substantially increases the risk of developing cancer at an early age. While only about ~300 cases have been reported to date, BSyn is part of a group of rare DNA damage response and repair disorders. The gene BLM, located at 15q26.1, encodes for the BLM protein, a RecQ DNA Helicase family protein. A recurrent mutation known as BLMAsh, which is common among Ashkenazi Jews, is responsible for approximately 30% of BSyn cases, while the remaining 70% of cases are caused by multiple other mutations with full or partial loss of function and a range of resulting phenotypes.

BLM pathogenic variants that cause Bloom syndrome result in DNA repair defects which in turn result in chromosome breakages and rearrangements. The abnormal DNA repair is responsible for the increased risk for cancer. Greater knowledge of its mechanisms will be not only beneficial for patients with Bloom syndrome but may also translate into clinical innovations for cancer therapy in general.

We are seeking grant applications to increase the rate of discovery of the mechanisms of BSyn and, importantly, lead to treatments and/or cures for BSyn. While the RFA is intentionally broad in scope, priority will be given to grants that cover the following areas:

  1. Improve knowledge of Bloom syndrome tumor biology, including, but not limited to tumor models, tumor sequencing to determine a tumor signature for BSyn, molecular surveillance for tumors, as well as a centralized registry of validated tissue (coordination of sampling, storing and distribution of samples). One 2-year grant for up to $150,000 (total cost).

  2. Literature review, critical assessment & study proposal, regarding:

      i.        The impact of sunlight and radiation in BSyn.

      ii.        Safety & efficacy of cancer treatments in BSyn including modalities, regimes and dosages.

    iii.        Utility of existing data sets as a natural history study and/or control arm for future clinical trials.

    iv.        Gene therapy for BSyn.

    v.         Why and how BSyn can be a model for cancer development in general.

    These projects will involve a critical review of currently available information and outline proposed studies that could be performed to better understand the topic(s) in question. Up to four one-year grants for up to $50,000 each (total cost).

  3.  Global cancer surveillance & novel cancer research in Bloom Syndrome, including, but not limited to, establishment of BSyn tumor organoids, collection and analyses of patient-derived blood samples, microbiome studies, and hematopoietic stem cell health and dysfunction studies. One 2-year grant for up to $150,000 (total cost).

Eligibility

Non-profits. All individuals holding a faculty-level appointment at an academic institution or a senior position at a non-profit institution or foundation are eligible to respond to this RFA.

Commercial entities. We will consider applications from commercial entities if a principal investigator of appropriate experience is identified.

Intellectual property created as a result of this funding will be assigned to the home institution of the inventors who presumably would be employees of the company. We expect that grants provided to commercial entities be matched dollar for dollar. Note that the budget should cover the entire scope of work and should include the Bloom Syndrome Association award and the company’s match. We will need assurance in the grant contract that the company will diligently develop the project.

Letters of Interest (LOI) are due Friday, September 27, 2024 by 8pm ET.

To Apply:

  1. Please review the Bloom Syndrome Grant Program RFA Guidelines.

  2. Complete the Application Form on Submittable.


For any scientific inquiries regarding this grant please email Debbie Requesens

For any administrative inquiries regarding this grant please email psom-odcadmin@pobox.upenn.edu

View Event →
May
27

Bloom Syndrome Grant Program

 
 

Bloom Syndrome Grant Program

The Orphan Disease Center (ODC) at the University of Pennsylvania is pleased to announce the Bloom Syndrome Grant Program. Bloom syndrome is an ultra-rare multi system disorder that substantially increases the risk of developing cancer at an early age. While only about ~300 cases have been reported to date, Bloom syndrome is part of a group of rare DNA damage response and repair disorders. BLM pathogenic variants that cause Bloom syndrome results in DNA repair defects which results in a chromosome breaks and rearrangements. The abnormal DNA repair is responsible for the increased risk for cancer. Greater knowledge of its mechanisms will be beneficial not only for patients of Bloom syndrome but also could be translated to the clinic for cancer therapy.

We are seeking grant applications that progress the discovery or development of treatments and/or cures for Bloom Syndrome. While the RFA is broad in scope, priority will be given to grants that cover the following areas:

 1)    Two-year grant for $150,000 (total cost): Improve knowledge of tumor biology, including, but not limited to tumor models, tumor sequencing and tumor signature for Bloom Syndrome, molecular surveillance for tumors, as well as a centralized registry of validated tissue (coordination of sampling, storing and distribution of samples).

 2)    Two-year grant for $100,000 (total cost): Novel therapeutic approaches for Bloom Syndrome, including, but not limited to, techniques in genome editing, RNA-based mechanisms, biologics, novel cell-based therapeutics, and development of novel therapeutic compounds, including through small molecule repurposing or screening against validated phenotypes in human cellular systems.


Eligibility

Non-profits. All individuals holding a faculty-level appointment at an academic institution or a senior position at a non-profit institution or foundation are eligible to respond to this RFA. Intellectual property created as a result of this funding will be assigned to the home institution of inventors according to standard institutional technology transfer policies. It is expected that these institutions will aggressively license these inventions to appropriate commercial entities with diligence provisions incorporated into these contracts.

Commercial entities. We will accept applications from commercial entities as long as a principal investigator of appropriate experience is identified. Intellectual property created as a result of this funding will be assigned to the home institution of inventors which presumably would be employees of the company. We expect grants provided to commercial entities be matched dollar for dollar. Note that the budget should cover the entire scope of work and should include the ODC award and the company’s match. We will need assurance in the grant contract that the company will diligently complete the project.

This Request for Applications (RFA) is open to all academic scientists and commercial entities in the international research community


Full applications are due Friday, May 27, 2022 by invitation only.

To Apply:

  1. Please review the Bloom Syndrome Grant Program RFA Guidelines.

  2. Complete the Cover Page to be uploaded with full application.

  3. Complete the Budget Form to be uploaded with fill application.

  4. Complete the Application Form on Submittable.


For any scientific inquiries regarding this grant please email Debbie Requesens

For any administrative inquiries regarding this grant please email Samantha Charleston.

View Event →